BioLineRx Ltd (BLRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioLineRx Ltd (BLRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH10103D
  • |
  • Pages: 69
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company focuses mainly on cancer and immunology. Its's product pipeline includes BL-8040, a short peptide for multiple cancer and hematological indications; BL-5010, a novel medical device for non-surgical removal of skin lesions; and AGI-134 a synthetic alpha-gal immunotherapy for solid tumors. BioLineRx's pipeline also comprises BL-1230 and BL-9020 in preclinical development. The company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel. BioLineRx is headquartered in Modi'in, Israel.

BioLineRx Ltd (BLRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioLineRx Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 10

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Agalimmune Raises USD2 Million in Venture Financing 13

Agalimmune Raises Funds Through Venture Financing Round 14

Private Equity 15

BVF Partners to Invest Additional USD9.6 Million in BioLineRx 15

Partnerships 16

BioLineRx Enters into Agreement with Genentech 16

BioLineRx Forms Joint Venture with I-Bridge Capital 17

BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 18

BioLineRx Expands Licensing Agreement with Merck 19

BioLineRx Enters into Agreement with Novartis Pharma 20

BioLineRx Enters Into Co-Development Agreement With JHL Biotech 21

Licensing Agreements 23

BioLineRx Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 23

BGN Tech Enters into Licensing Agreement with BioLineRx 24

BioLineRx Enters into Licensing Agreement with Hadassah Medical Organization 25

Agalimmune Enters into Licensing Agreement with KODE Biotech 26

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 27

BioLineRx Enters Into Licensing Agreement with Jiangsu Chia-tai Tianqing Pharma For BL-8030 28

BioLineRx Enters Into Licensing Agreement With Biokine Therapeutics For BL-8040 29

BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030 31

BioLineRx Enters into Licensing Agreement for Treatment of Neuropathic Pain 32

University of Massachusetts Medical School Enters Into Licensing Agreement With Agalimmune For Alphaject 33

BioLineRx Enters Into Licensing Agreement With Yissum, B.G. Negev Technologies And Hadasit Medical 34

BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020 36

Equity Offering 37

BioLineRx to Raise up to USD30 Million in Public Offering of American Depositary Shares 37

BioLineRx Raises USD28.8 Million Public Offering of American Depositary Shares 38

BioLineRx Raises USD28.8 Million in Public Offering of American Depositary Shares 40

BioLineRx to Raise up to USD20 Million in Private Placement of American Depositary Shares 42

BioLineRx Completes Public Offering Of American Depositary Shares For USD 24.2 Million 43

BioLineRx Completes Private Placement Of American Depositary Shares For USD 8 Million 44

BioLineRx Completes Private Placement Of American Depositary Shares For USD 15 Million 45

Acquisition 46

BioLineRx Acquires Agalimmune 46

BioLineRx Ltd-Key Competitors 47

BioLineRx Ltd-Key Employees 48

BioLineRx Ltd-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Joint Venture 49

Recent Developments 50

Financial Announcements 50

Aug 13, 2018: BioLineRx reports second quarter 2018 financial results 50

May 22, 2018: BioLineRx Reports First Quarter 2018 Financial Results 52

Mar 06, 2018: BioLineRx Reports Year End 2017 Financial Results 54

Nov 21, 2017: BioLineRx Reports Third Quarter 2017 Financial Results 57

Aug 08, 2017: BioLineRx announces Q2 2017 Financial Results 59

May 25, 2017: BioLineRx Reports First Quarter 2017 Financial Results 61

Mar 23, 2017: BioLineRx Reports Year End 2016 Financial Results 63

Clinical Trials 65

May 03, 2017: BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA 65

Mar 20, 2017: BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment 66

Jan 17, 2017: BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer 67

Appendix 68

Methodology 68

About GlobalData 68

Contact Us 68

Disclaimer 68

List of Figures

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

BioLineRx Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioLineRx Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioLineRx Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 10

BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Agalimmune Raises USD2 Million in Venture Financing 13

Agalimmune Raises Funds Through Venture Financing Round 14

BVF Partners to Invest Additional USD9.6 Million in BioLineRx 15

BioLineRx Enters into Agreement with Genentech 16

BioLineRx Forms Joint Venture with I-Bridge Capital 17

BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 18

BioLineRx Expands Licensing Agreement with Merck 19

BioLineRx Enters into Agreement with Novartis Pharma 20

BioLineRx Enters Into Co-Development Agreement With JHL Biotech 21

BioLineRx Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 23

BGN Tech Enters into Licensing Agreement with BioLineRx 24

BioLineRx Enters into Licensing Agreement with Hadassah Medical Organization 25

Agalimmune Enters into Licensing Agreement with KODE Biotech 26

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 27

BioLineRx Enters Into Licensing Agreement with Jiangsu Chia-tai Tianqing Pharma For BL-8030 28

BioLineRx Enters Into Licensing Agreement With Biokine Therapeutics For BL-8040 29

BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030 31

BioLineRx Enters into Licensing Agreement for Treatment of Neuropathic Pain 32

University of Massachusetts Medical School Enters Into Licensing Agreement With Agalimmune For Alphaject 33

BioLineRx Enters Into Licensing Agreement With Yissum, B.G. Negev Technologies And Hadasit Medical 34

BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020 36

BioLineRx to Raise up to USD30 Million in Public Offering of American Depositary Shares 37

BioLineRx Raises USD28.8 Million Public Offering of American Depositary Shares 38

BioLineRx Raises USD28.8 Million in Public Offering of American Depositary Shares 40

BioLineRx to Raise up to USD20 Million in Private Placement of American Depositary Shares 42

BioLineRx Completes Public Offering Of American Depositary Shares For USD 24.2 Million 43

BioLineRx Completes Private Placement Of American Depositary Shares For USD 8 Million 44

BioLineRx Completes Private Placement Of American Depositary Shares For USD 15 Million 45

BioLineRx Acquires Agalimmune 46

BioLineRx Ltd, Key Competitors 47

BioLineRx Ltd, Key Employees 48

BioLineRx Ltd, Subsidiaries 49

BioLineRx Ltd, Joint Venture 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

BioLineRx Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com